Gilles Boschetti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9115355/publications.pdf

Version: 2024-02-01

63	2,747	236833	189801
papers	citations	25 h-index	50 g-index

63	63	63	4468
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Single-Cell Analysis of Crohnâ€™s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. Cell, 2019, 178, 1493-1508.e20.	13.5	519
2	Effectiveness and Safety of Vedolizumab Induction Therapy forÂPatients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1593-1601.e2.	2.4	168
3	A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. American Journal of Gastroenterology, 2010, 105, 2617-2625.	0.2	164
4	GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer, 2014, 14, 183.	1.1	163
5	Postoperative Complications after Ileocecal Resection in Crohnâ€™s Disease: A Prospective Study From the REMIND Group. American Journal of Gastroenterology, 2017, 112, 337-345.	0.2	138
6	Pathological Response to Neoadjuvant Chemotherapy: A New Prognosis Tool for the Curative Management of Peritoneal Colorectal Carcinomatosis. Annals of Surgical Oncology, 2014, 21, 2608-2614.	0.7	116
7	Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohnâ€™s Disease. American Journal of Gastroenterology, 2015, 110, 865-872.	0.2	114
8	Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an openâ€label, prospective and randomised clinical trial. Alimentary Pharmacology and Therapeutics, 2017, 46, 142-149.	1.9	104
9	Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months. Clinical Gastroenterology and Hepatology, 2017, 15, 1750-1757.e3.	2.4	102
10	Therapy with anti-TNFÎ± antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases. Inflammatory Bowel Diseases, 2011, 17, 160-170.	0.9	93
11	Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut, 2020, 69, 1206-1212.	6.1	92
12	Neopterin Is a Novel Reliable Fecal Marker as Accurate as Calprotectin for Predicting Endoscopic Disease Activity in Patients with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2013, 19, 1043-1052.	0.9	89
13	Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2015, 21, 331-336.	0.9	67
14	Mouse and Human Liver Contain Immunoglobulin Aâ€“Secreting Cells Originating From Peyer's Patches and Directed Against Intestinal Antigens. Gastroenterology, 2016, 151, 311-323.	0.6	65
15	Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease. American Journal of Gastroenterology, 2020, 115, 1084-1093.	0.2	40
16	A Perioperative Clinical Pathway Can Dramatically Reduce Failure-to-rescue Rates After Cytoreductive Surgery for Peritoneal Carcinomatosis. Annals of Surgery, 2017, 265, 806-813.	2.1	38
17	High-dimensional immune phenotyping and transcriptional analyses reveal robust recovery of viable human immune and epithelial cells from frozen gastrointestinal tissue. Mucosal Immunology, 2018, 11, 1684-1693.	2.7	38
18	Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course. Journal of Crohn's and Colitis, 2015, 9, 445-451.	0.6	37

#	Article	IF	Citations
19	Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 2048-2053.	0.9	36
20	Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, 930-935.	0.6	34
21	Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 2610-2612.	2.4	34
22	Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?. Inflammatory Bowel Diseases, 2018, 24, 2078-2085.	0.9	30
23	Zebrafish modeling of intestinal injury, bacterial exposures, and medications defines epithelial in vivo responses relevant to human inflammatory bowel disease. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	30
24	Comparison of shortâ€•and longâ€term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to antiâ€tumour necrosis factor therapy. Alimentary Pharmacology and Therapeutics, 2021, 53, 1289-1299.	1.9	30
25	GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. BMC Cancer, 2015, 15, 47.	1.1	29
26	Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2017, 23, 126-132.	0.9	26
27	Enrichment of Circulating and Mucosal Cytotoxic CD8⁺T Cells Is Associated with Postoperative Endoscopic Recurrence in Patients with Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2016, 10, 338-345.	0.6	25
28	Gut Inflammation in Mice Triggers Proliferation and Function of Mucosal Foxp3+Regulatory T Cells but Impairs Their Conversion from CD4+T Cells. Journal of Crohn's and Colitis, 2017, 11, 105-117.	0.6	24
29	Intestinal dendritic cell licensing through Toll-like receptor 4 is required for oral tolerance in allergic contact dermatitis. Journal of Allergy and Clinical Immunology, 2018, 141, 163-170.	1.5	24
30	Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. Future Oncology, 2012, 8, 751-756.	1.1	23
31	Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Digestive and Liver Disease, 2017, 49, 11-16.	0.4	23
32	CD4+ T Cells and Lactobacillus casei Control Relapsing Colitis Mediated by CD8+ T Cells. Journal of Immunology, 2009, 183, 5477-5486.	0.4	22
33	Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. Digestive and Liver Disease, 2014, 46, 875-880.	0.4	21
34	Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study. Journal of Crohn's and Colitis, 2018, 12, 1089-1096.	0.6	15
35	Human Herpesvirus 8-Associated Colorectal KaposiÊ¼s Sarcoma Occurring in a Drug-induced Immunocompromised Patient with Refractory Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, E12-E15.	0.9	14
36	IBD-INFO Questionnaire: A Multicenter French Up-to-Date Survey of Patient Knowledge in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 943-952.	0.9	14

#	Article	IF	Citations
37	Endoscopic and histologic characteristics of serrated lesions. World Journal of Gastroenterology, 2015, 21, 2896.	1.4	14
38	Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?. European Journal of Gastroenterology and Hepatology, 2010, 22, 1015-1018.	0.8	12
39	Early detection of antiâ€drug antibodies during initiation of antiâ€tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 1190-1200.	1.9	11
40	Faster and less invasive tools to identify patients with ileal colonization by adherentâ€invasive E. coli in Crohn's disease. United European Gastroenterology Journal, 2021, 9, 1007-1018.	1.6	11
41	TRIM33 deficiency in monocytes and macrophages impairs resolution of colonic inflammation. EBioMedicine, 2019, 44, 60-70.	2.7	10
42	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Digestive and Liver Disease, 2022, 54, 309-315.	0.4	10
43	Blockade of LTB4/BLT1 pathway improves CD8+ T-cell-mediated colitis. Inflammatory Bowel Diseases, 2011, 17, 279-288.	0.9	9
44	Identification of Mycobacterium cosmeticum sp. as a novel colitogenic infectious agent in a nonimmunocompromised patient. Inflammatory Bowel Diseases, 2011, 17, E128-E130.	0.9	9
45	An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. Journal of Geriatric Oncology, 2018, 9, 373-381.	0.5	9
46	Plasmacytoid dendritic cells are dispensable for noninfectious intestinal IgA responses in vivo. European Journal of Immunology, 2016, 46, 354-359.	1.6	8
47	Low Levels of Fecal Calprotectin 3ÂMonths After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohnâ€™s Disease. Digestive Diseases and Sciences, 2021, 66, 4429-4435.	1.1	8
48	Costs of CrohnÊ¼s Disease According to Severity States in France. Inflammatory Bowel Diseases, 2016, 22, 2924-2932.	0.9	6
49	No Difference of Adalimumab Pharmacokinetics When Dosed at 40Âmg Every Week or 80Âmg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification. Digestive Diseases and Sciences, 2021, 66, 2744-2749.	1.1	6
50	Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels. Inflammatory Bowel Diseases, 2021, , .	0.9	5
51	Infliximab induces clinical resolution of sacroiliitis that coincides with increased circulating FOXP3+ T cells in a patient with IPEX syndrome. Joint Bone Spine, 2020, 87, 483-486.	0.8	4
52	Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions. Digestive Diseases, 2018, 36, 417-426.	0.8	3
53	Impact of the Ileal Microbiota on Surgical Site Infections in Crohnâ€™s Disease: A Nationwide Prospective Cohort. Journal of Crohn's and Colitis, 2022, , .	0.6	3
54	Su1281 Serrated Polyps in Patients With Inflammatory Bowel Disease: Endoscopic Characteristics Different From Serrated Polyps in the General Population. Gastroenterology, 2014, 146, S-424.	0.6	2

#	Article	IF	Citations
55	Facteurs psychosociaux et risque de rechute au cours de la maladie de Crohn. Annales Medico-Psychologiques, 2016, 174, 461-467.	0.2	2
56	Yield of Neoplasia by Confocal Laser Endomicroscopy in the Chronic Atrophic Gastritis. Gastroenterology, 2011, 140, S-748-S-749.	0.6	1
57	Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohnâ€™s disease. Scandinavian Journal of Gastroenterology, 2016, 51, 727-730.	0.6	1
58	Management of chemotherapyâ€induced anemia (CIA) with biosimilar epoetin alfa (Binocrit) in patients with colorectal cancer (CC): An interim analysis of an ongoing French national observational study (The OncoBOS study).. Journal of Clinical Oncology, 2015, 33, 742-742.	0.8	1
59	Overview of French Routine Clinical Practice for the Management of Chemotherapy-Induced Anemia (CIA) with Biosimilar Epoetin Alfa in 563 Patients with Lymphoid Malignancies: A National Observational Study (The OncoBOS study). Blood, 2015, 126, 3342-3342.	0.6	1
60	Abdominal necrotic abscess from colonic fistula treated endoscopically. Gastrointestinal Endoscopy, 2015, 81, 1026-1027.	0.5	0
61	Response to Dai et al.. American Journal of Gastroenterology, 2015, 110, 1242.	0.2	0
62	P045 HIGH DIMENSIONAL IMMUNE PHENOTYPING AND TRANSCRIPTIONAL ANALYSES REVEAL ROBUST RECOVERY OF VIABLE HUMAN IMMUNE AND EPITHELIAL CELLS FROM CRYOPRESERVED INTESTINAL TISSUE. Gastroenterology, 2018, 154, S23-S24.	0.6	0
63	Management of chemotherapyâ€induced anemia (CIA) with biosimilar epoetin alfa (Binocrit) in patients with pancreatic cancer (PC): An interim analysis of an ongoing French national observational study (The OncoBOS study).. Journal of Clinical Oncology, 2015, 33, 479-479.	0.8	0